HRP20220310T1 - Inhibitori glukozilceramid sintaze - Google Patents
Inhibitori glukozilceramid sintaze Download PDFInfo
- Publication number
- HRP20220310T1 HRP20220310T1 HRP20220310TT HRP20220310T HRP20220310T1 HR P20220310 T1 HRP20220310 T1 HR P20220310T1 HR P20220310T T HRP20220310T T HR P20220310TT HR P20220310 T HRP20220310 T HR P20220310T HR P20220310 T1 HRP20220310 T1 HR P20220310T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- compound
- group
- alkyl
- alkoxy
- Prior art date
Links
- 239000003892 ceramide glucosyltransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 6
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 5
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 201000002648 nephronophthisis Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 claims 3
- 208000015872 Gaucher disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 108091000114 ceramide glucosyltransferase Proteins 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000002132 lysosomal effect Effects 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 2
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 claims 2
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 208000024720 Fabry Disease Diseases 0.000 claims 2
- 102000004547 Glucosylceramidase Human genes 0.000 claims 2
- 108010017544 Glucosylceramidase Proteins 0.000 claims 2
- 208000007696 Multicystic Dysplastic Kidney Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 2
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 2
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 2
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000002981 neuropathic effect Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 2
- OJCLMSVFVVKWJX-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl n-[2-[3-(4-fluorophenyl)phenyl]propan-2-yl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C(C=1)=CC=CC=1C1=CC=C(F)C=C1 OJCLMSVFVVKWJX-UHFFFAOYSA-N 0.000 claims 1
- 208000006515 AB Variant Tay-Sachs Disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000036075 Autosomal dominant tubulointerstitial kidney disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 claims 1
- 208000037310 Gaucher disease type 2 Diseases 0.000 claims 1
- 208000037311 Gaucher disease type 3 Diseases 0.000 claims 1
- 102000016871 Hexosaminidase A Human genes 0.000 claims 1
- 108010053317 Hexosaminidase A Proteins 0.000 claims 1
- 102000016870 Hexosaminidase B Human genes 0.000 claims 1
- 108010053345 Hexosaminidase B Proteins 0.000 claims 1
- 208000034946 Juvenile nephronophthisis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- YFHRCLAKZBDRHN-MRXNPFEDSA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)NC(C)(C)C(N=1)=CSC=1C1=CC=C(F)C=C1 YFHRCLAKZBDRHN-MRXNPFEDSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 150000002339 glycosphingolipids Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 201000001228 nephronophthisis 1 Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (19)
1. Spoj za upotrebu u liječenju lizosomske bolesti nakupljanja kod subjekta kod kojeg je dijagnosticirana navedena bolest, koji se sastoji od davanja subjektu učinkovite količine spoja, te po izboru dodatno obuhvaća korak davanja subjektu terapeutski učinkovite količine lizosomalnog enzima, naznačen time što je spoj predstavljen sa sljedećom strukturnom formulom,
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu:
n je 1 ili 2;
m je 1;
p je 1;
t je 0 ili 1;
y je 1;
z je 0 ili 1;
E je O;
X1 je CR1;
X2 je O;
X3 je -NH;
X4 je izravna veza ili CR4R5;
X5 je izravna veza ili O;
R1 je H ili (C1-C6)alkil;
R4 i R5 su neovisno odabrani od (C1-C6)alkila, ili uzeti zajedno s ugljikom na koji su vezani tvore spiro (C3-C10)cikloalkilni prsten;
R6 je -H ili (C1-C6)alkil;
A1 je (C6-C12)aril ili (C2-C9)heteroaril, po izboru supstituiran s jednim ili više supstituenata odabranih iz skupine koju čine: halo; (C1-C6)alkil po izboru supstituiran s jednim do tri halo; (C1-C6)alkoksi; i -OH; i
A2 je (C6-C12)aril ili (C2-C9)heteroaril, supstituiran s jednim ili više supstituenata odabranih iz skupine koju čine: (C2-C9)heterocikloalkil; R8R9N-CO- pri čemu R8 i R9 su svaki neovisno odabrani iz skupine koju čine vodik i (C1-C6)alkil ili R8 i R9 mogu se uzeti zajedno s dušikom na koji su vezani tako da tvore (C2-C9)heterocikloalkilnu skupinu koja je izborno supstituirana s jednom do tri halo skupine; (C1-C6)alkilsulfonil izborno supstituiran s jednom ili dvije skupine odabrane od (C1-C6)alkoksi i (C3-C10)cikloalkil; (C1-C6)alkil supstituiran s jednim do četiri supstituenta odabrana iz skupine koju čine hidroksi, (C1-C6)alkoksi, (C1-C6)alkoksi(C1-C6)alkoksi, (C2-C9)heterocikloalkil, i (C2-C9)heteroaril; i (C1-C6)alkiloksi supstituiran s jednim do četiri supstituenta odabrana iz skupine koju čine cijano, (C1-C6)alkoksi, (C2-C9)heterocikloalkil, i (C2-C9)heteroaril.
2. Spoj za upotrebu prema patentnom zahtjevu 1, naznačen time što n je 1; t je 0; y je 1 i z je 1.
3. Spoj za upotrebu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time što R6 je H.
4. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što R1 je vodik ili metil.
5. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što X4 je CR4R5 pri čemu R4 i R5 su svaki neovisno metil.
6. Spoj za upotrebu prema patentnom zahtjevu 1, naznačen time što je spoj predstavljen formulom
[image]
ili njegova farmaceutski prihvatljiva sol.
7. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time što je lizosomska bolest nakupljanja posljedica defekta glikosfingolipidnog puta, na pr. pri čemu je lizosomska bolest nakupljanja odabrana iz skupine koju čine Gaucherova bolest, Fabryeva bolest, GM1-gangliozidoza, nedostatak GM2 aktivatora, Tay-Sachs i Sandhoff, posebno pri čemu je lizosomska bolest nakupljanja Fabryeva bolest, Gaucherova bolest tip 2 ili Gaucherova bolest tip 3.
8. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što je lizosomski enzim odabran iz skupine koju čine glukocerebrozidaza, alfa-galaktozidaza A, heksosaminidaza A, heksosaminidaza B i GM1-gangliozid-β-galaktozidaza, naročito pri čemu je lizosomski enzim alfa-galaktozidaza A ili glukocerebrozidaza.
9. Spoj za upotrebu u liječenju, ublažavanju ili prevenciji cističnih bolesti, npr. pri čemu je cistična bolest bubrega, po izboru odabrana iz niza koji čine stečena bubrežna cistična bolest (ARCD), cistična bolest povezana s dijalizom, autosomno dominantna policistična bolest bubrega (ADPKD), autosomno recesivna policistična bolest bubrega (ARPKD), kongenitalni multicistični bubreg (CMK), multicistični displastični bubreg, terminalna bubrežna bolest (ESRD), medularni spužvasti bubreg (MSK), kompleks nefronoftiza-medularna cistična bolest bubrega (NMCD), kompleks nefronoftiza-uremična medularna cistična bolest, juvenilna nefronoftiza, medularna cistična bolest, karcinom bubrežnih stanica (RCC), tuberozna skleroza (TS), i sindrom von Hippel-Lindau (VHLS), pri čemu navedeni spoj je (S)-kinuklidin-3-il (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)karbamat, ili kinuklidin-3-il (2-(4'-fluoro-[1,1'-bifenil]-3-il)propan-2-il)karbamat, ili spoj formule I kako je definiran u bilo kojem od patentnih zahtjeva 1 do 6.
10. Spoj predstavljen sljedećom strukturnom formulom,
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time što:
n je 1 ili 2;
m je 1;
p je 1;
t je 0 ili 1;
y je 1;
z je 1;
E je O;
X1 je CR1;
X2 je O;
X3 je -NH;
X4 je CR4R5;
X5 je izravna veza ili O;
R1 je H ili (C1-C6)alkil;
R4 i R5 su neovisno odabrani od (C1-C6)alkil, ili uzeti zajedno s ugljikom na koji su vezani tvore spiro (C3-C10)cikloalkilni prsten;
R6 je -H ili (C1-C6)alkil;
A1 je (C6-C12)aril ili (C2-C9)heteroaril, po izboru supstituiran s jednim ili više supstituenata odabranih iz skupine koju čine: halo; (C1-C6)alkil po izboru supstituiran s jednim do tri halo; (C1-C6)alkoksi; i -OH; i
A2 je (C6-C12)aril ili (C2-C9)heteroaril, supstituiran s jednim ili više supstituenata odabranih iz skupine koju čine: (C2-C9)heterocikloalkil; R8R9N-CO- pri čemu R8 i R9 su svaki neovisno odabrani iz skupine koju čine vodik i (C1-C6)alkil ili R8 i R9 mogu se uzeti zajedno s dušikom na koji su vezani tako da tvore (C2-C9)heterocikloalkilnu skupinu koja je izborno supstituirana s jednom do tri halo skupine; (C1-C6)alkilsulfonil izborno supstituiran s jednom ili dvije skupine odabrane od (C1-C6)alkoksi i (C3-C10)cikloalkil; (C1-C6)alkil supstituiran s jednim do četiri supstituenta odabrana iz skupine koju čine hidroksi, (C1-C6)alkoksi, (C1-C6)alkoksi(C1-C6)alkoksi, (C2-C9)heterocikloalkil, i (C2-C9)heteroaril; i (C1-C6)alkiloksi supstituiran s jednim do četiri supstituenta odabrana iz skupine koju čine cijano, (C1-C6)alkoksi, (C2-C9)heterocikloalkil, i (C2-C9)heteroaril.
11. Spoj prema patentnom zahtjevu 10, naznačen time što n je 1; t je 0; y je 1 i z je 1.
12. Spoj prema patentnom zahtjevu 10 ili zahtjevu 11, naznačen time što R1 je vodik ili metil.
13. Spoj prema bilo kojem od patentnih zahtjeva 10 do 12, naznačen time što X4 je CR4R5 pri čemu su R4 i R5 svaki neovisno metil.
14. Spoj prema bilo kojem od patentnih zahtjeva 10 do 12, naznačen time što X4 je CR4R5 pri čemu su R4 i R5 uzeti zajedno s ugljikom na koji su vezani tako da tvore spiro ciklopropilni prsten.
15. Spoj predstavljen formulom
[image]
ili njegova farmaceutski prihvatljiva sol.
16. Farmaceutski pripravak naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 10 do 15 i najmanje jedan farmaceutski prihvatljiv nosač.
17. Spoj prema bilo kojem od patentnih zahtjeva 10 do 15, ili farmaceutski pripravak prema zahtjevu 16, za upotrebu u terapiji.
18. Spoj prema bilo kojem od patentnih zahtjeva 10 do 15, ili farmaceutski pripravak prema zahtjevu 16, za uporabu u liječenju bolesti ili poremećaja posredovanog glukozilceramid sintazom (GCS) ili bolesti ili poremećaja u kojem je implicirana GCS, pri čemu je bolest ili poremećaj rak, metabolički poremećaj, ili neuropatska bolest.
19. Spoj ili farmaceutski pripravak za upotrebu prema patentnom zahtjevu 18, naznačen time što je neuropatska bolest Alzheimerova bolest ili Parkinsonova bolest.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699714P | 2012-09-11 | 2012-09-11 | |
| EP13765893.6A EP2895484B1 (en) | 2012-09-11 | 2013-09-10 | Glucosylceramide synthase inhibitors |
| PCT/US2013/058896 WO2014043068A1 (en) | 2012-09-11 | 2013-09-10 | Glucosylceramide synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220310T1 true HRP20220310T1 (hr) | 2022-05-13 |
Family
ID=49226563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220310TT HRP20220310T1 (hr) | 2012-09-11 | 2013-09-10 | Inhibitori glukozilceramid sintaze |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US20150210681A1 (hr) |
| EP (2) | EP2895484B1 (hr) |
| JP (1) | JP6430943B2 (hr) |
| KR (1) | KR102216532B1 (hr) |
| CN (3) | CN108864076B (hr) |
| AR (1) | AR092522A1 (hr) |
| AU (1) | AU2013315715A1 (hr) |
| BR (1) | BR112015005227A2 (hr) |
| CA (1) | CA2884144C (hr) |
| CL (1) | CL2015000529A1 (hr) |
| CR (1) | CR20150150A (hr) |
| DK (1) | DK2895484T3 (hr) |
| DO (1) | DOP2015000039A (hr) |
| EA (2) | EA038536B1 (hr) |
| ES (1) | ES2911685T3 (hr) |
| GT (1) | GT201500051A (hr) |
| HK (1) | HK1212681A1 (hr) |
| HR (1) | HRP20220310T1 (hr) |
| HU (1) | HUE058085T2 (hr) |
| IL (1) | IL237355B (hr) |
| JO (1) | JOP20130273B1 (hr) |
| LT (1) | LT2895484T (hr) |
| MA (1) | MA37975B2 (hr) |
| MX (2) | MX2020002867A (hr) |
| MY (1) | MY186824A (hr) |
| NZ (1) | NZ706296A (hr) |
| PE (1) | PE20150734A1 (hr) |
| PH (1) | PH12015500431A1 (hr) |
| PL (1) | PL2895484T3 (hr) |
| PT (1) | PT2895484T (hr) |
| RS (1) | RS63130B1 (hr) |
| SG (2) | SG11201501538VA (hr) |
| SI (1) | SI2895484T1 (hr) |
| TN (1) | TN2015000091A1 (hr) |
| TW (1) | TWI627171B (hr) |
| UA (1) | UA118747C2 (hr) |
| UY (1) | UY35024A (hr) |
| WO (1) | WO2014043068A1 (hr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| SG11201506415XA (en) * | 2013-03-15 | 2015-09-29 | Genzyme Corp | Method of preparing glucosylceramide synthase inhibitors |
| US20160361301A1 (en) * | 2013-12-11 | 2016-12-15 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
| MX2017001648A (es) * | 2014-08-04 | 2017-04-27 | Genzyme Corp | Biomarcadores de enfermedad poliquistica renal y usos de los mismos. |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| CN108700594B (zh) | 2015-11-18 | 2021-06-29 | 建新公司 | 多囊性肾病的生物标志物及其用途 |
| EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| KR20230109185A (ko) | 2016-06-07 | 2023-07-19 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| JP6878615B2 (ja) | 2017-03-23 | 2021-05-26 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体 |
| CN109111447A (zh) | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途 |
| EP3728265A1 (en) | 2017-12-21 | 2020-10-28 | BIAL - BioTech Investments, Inc. | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof |
| US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
| US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN109709202A (zh) * | 2018-12-29 | 2019-05-03 | 辉源生物科技（上海）有限公司 | 一种半乳糖神经酰胺转移酶抑制剂药物的快速筛选方法 |
| EP3920912A1 (en) * | 2019-02-04 | 2021-12-15 | Genzyme Corporation | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs) |
| WO2020198711A1 (en) * | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for use as proteolysis targeting chimera ligands |
| EP3982958A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| JP2022536773A (ja) | 2019-06-14 | 2022-08-18 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 |
| US20220324860A1 (en) | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| CR20210580A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b |
| AU2020290772A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| EP4005638A4 (en) | 2019-07-29 | 2023-07-05 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| EP4005637A4 (en) | 2019-07-29 | 2023-07-19 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| KR102483492B1 (ko) * | 2019-09-02 | 2023-01-02 | 한양대학교 에리카산학협력단 | 2,5-이치환된 피리미딘 유도체 및 이를 포함하는 약학적 조성물 |
| KR20210059632A (ko) * | 2019-11-15 | 2021-05-25 | 주식회사유한양행 | 신규의 2,3-다이하이드로-1h-인덴 또는 2,3-다이하이드로벤조퓨란 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물 |
| WO2021096241A1 (en) * | 2019-11-15 | 2021-05-20 | Yuhan Corporation | Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same |
| TW202142236A (zh) * | 2020-02-03 | 2021-11-16 | 美商健臻公司 | 用於治療與溶體儲積症相關的神經症狀之方法 |
| WO2021212032A1 (en) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
| TW202220648A (zh) | 2020-07-24 | 2022-06-01 | 美商健臻公司 | 包含芬谷司他(venglustat)之醫藥組合物 |
| BR112023022015A2 (pt) * | 2021-05-11 | 2023-12-26 | Green Cross Corp | Novos compostos que têm atividade inibidora contra glucosilceramida sintase ou sal farmaceuticamente aceitável da mesma, processos para preparar os mesmos e respectivas composições farmacêuticas |
| WO2023101895A1 (en) * | 2021-11-30 | 2023-06-08 | Merck Sharp & Dohme Llc | Fused pyrazole urea analogs as glucosylceramide synthase inhibitors |
| WO2023172475A2 (en) * | 2022-03-11 | 2023-09-14 | Merck Sharp & Dohme Llc | Non-aromatic cyclic-pyrimidine analogs as glucosylceramide synthase inhibitors |
| WO2023177563A2 (en) * | 2022-03-14 | 2023-09-21 | Merck Sharp & Dohme Llc | Fused pyrazole amide analogs as glucosylceramide synthase inhibitors |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (hr) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4593034A (en) * | 1984-04-06 | 1986-06-03 | A. H. Robins Company, Inc. | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides |
| AU611976B2 (en) | 1987-12-24 | 1991-06-27 | John Wyeth & Brother Limited | Aroyl urea and carbamic acid derivatives of azabicyclo compounds |
| EP0353372B1 (en) * | 1988-08-04 | 1993-02-03 | Synthelabo | Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| IT1228293B (it) | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | Benzoderivati di composti eterociclici contenenti azoto. |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| GB9106571D0 (en) | 1991-03-27 | 1991-05-15 | Erba Carlo Spa | Derivatives of substituted imidazol-2-one and process for their preparation |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| WO1995021820A1 (fr) * | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau derive du carbamate et composition correspondante |
| US5468875A (en) * | 1994-12-22 | 1995-11-21 | American Home Products Corporation | 1-azabicycloheptane derivatives |
| JPH08198751A (ja) * | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | カルバメート誘導体 |
| WO1997017348A1 (en) | 1995-11-08 | 1997-05-15 | American Home Products Corporation | 1-azabicycloheptane derivatives and their pharmaceutical use |
| SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| JP2000515881A (ja) | 1996-07-29 | 2000-11-28 | フアーマシア・アンド・アツプジヨン・アー・ベー | アリールシクロアルカンカルボン酸エステル、その使用、薬剤組成物および調製 |
| DE69835367T2 (de) | 1997-10-29 | 2007-08-02 | Genzyme Corp., Framingham | Gentherapie für gaucher-krankheit |
| EP1125922A1 (en) | 1998-11-02 | 2001-08-22 | Welfide Corporation | Pyrrolidine compounds and medicinal utilization thereof |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| FR2791678B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
| MXPA02007632A (es) * | 2000-02-07 | 2004-08-23 | Abbott Gmbh & Co Kg | Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa. |
| GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| TR200400420T4 (tr) | 2000-06-27 | 2004-03-22 | Laboratorios S.A.L.V.A.T., S.A. | Arilalkilaminlerden türetilmiş karbamatlar. |
| AU2001284645A1 (en) * | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| AU2001284646A1 (en) * | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| EP1231212B1 (en) | 2001-02-06 | 2006-12-20 | Pfizer Products Inc. | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders |
| JP2003267977A (ja) | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
| DE10211415A1 (de) * | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
| ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| ES2393331T3 (es) | 2002-07-17 | 2012-12-20 | Actelion Pharmaceuticals Ltd. | Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa |
| JPWO2004011430A1 (ja) | 2002-07-25 | 2005-11-24 | アステラス製薬株式会社 | ナトリウムチャネル阻害剤 |
| SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| ATE378048T1 (de) * | 2002-12-06 | 2007-11-15 | The Feinstein Inst Medical Res | Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten |
| WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| TW200529860A (en) | 2003-12-22 | 2005-09-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| JP2007186422A (ja) | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | アリールスルフィド誘導体 |
| AU2005258274A1 (en) | 2004-06-23 | 2006-01-05 | The Feinstein For Medical Research | Method of treating ileus by pharmacological activation of cholinergic receptors |
| EP1811991B1 (en) | 2004-11-10 | 2018-11-07 | Genzyme Corporation | Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis |
| WO2006134318A1 (en) | 2005-06-11 | 2006-12-21 | Vernalis R & D Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| WO2007038367A1 (en) * | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| US20090170847A1 (en) * | 2006-01-23 | 2009-07-02 | Seung Chul Lee | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same |
| BRPI0707245A2 (pt) * | 2006-01-23 | 2011-04-26 | Crystalgenomics Inc | derivados de imidazopiridina que inibem a atividade de proteìna quinase, método para a preparação destes e composição farmacêutica contendo os mesmos |
| US20090318491A1 (en) * | 2006-01-27 | 2009-12-24 | Yale Univeristy | Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders |
| WO2008096870A1 (ja) * | 2007-02-09 | 2008-08-14 | Astellas Pharma Inc. | アザ架橋環化合物 |
| AU2008266960A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Diphenyl substituted alkanes |
| GB2466912B (en) | 2007-11-29 | 2012-01-04 | Hospital For Sick Children | Compositions and methods for treating lysosomal disorders |
| US8389517B2 (en) | 2008-07-28 | 2013-03-05 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| EP2154136A1 (en) | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
| WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| ES2533954T3 (es) * | 2009-04-21 | 2015-04-16 | Nerviano Medical Sciences S.R.L. | Derivados de resorcinol como inhibidores de HSP90 |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| LT3482767T (lt) | 2009-08-28 | 2022-01-10 | Icahn School Of Medicine At Mount Sinai | Didinamos dozės fermentų pakaitinė terapija, skirta rūgštinės sfingomielinazės nepakankamumui gydyti |
| US20110183938A1 (en) * | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
| BR112013023774B1 (pt) * | 2011-03-18 | 2022-01-11 | Genzyme Corporation | Inibidores de glicosilceramida sintase |
| ES2552754T1 (es) | 2012-09-11 | 2015-12-02 | Hospira Australia Pty Ltd | Formulaciones de daptomicina y usos de la misma |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
-
2013
- 2013-09-09 MA MA37975A patent/MA37975B2/fr unknown
- 2013-09-09 JO JOP/2013/0273A patent/JOP20130273B1/ar active
- 2013-09-10 PT PT137658936T patent/PT2895484T/pt unknown
- 2013-09-10 WO PCT/US2013/058896 patent/WO2014043068A1/en active Application Filing
- 2013-09-10 DK DK13765893.6T patent/DK2895484T3/da active
- 2013-09-10 EP EP13765893.6A patent/EP2895484B1/en active Active
- 2013-09-10 PE PE2015000308A patent/PE20150734A1/es unknown
- 2013-09-10 LT LTEPPCT/US2013/058896T patent/LT2895484T/lt unknown
- 2013-09-10 ES ES13765893T patent/ES2911685T3/es active Active
- 2013-09-10 EP EP22154095.8A patent/EP4098654A1/en active Pending
- 2013-09-10 EA EA201590554A patent/EA038536B1/ru not_active IP Right Cessation
- 2013-09-10 MX MX2020002867A patent/MX2020002867A/es unknown
- 2013-09-10 SG SG11201501538VA patent/SG11201501538VA/en unknown
- 2013-09-10 US US14/427,275 patent/US20150210681A1/en not_active Abandoned
- 2013-09-10 CA CA2884144A patent/CA2884144C/en active Active
- 2013-09-10 NZ NZ706296A patent/NZ706296A/en unknown
- 2013-09-10 EA EA202091568A patent/EA202091568A1/ru unknown
- 2013-09-10 SG SG10201701966RA patent/SG10201701966RA/en unknown
- 2013-09-10 CN CN201810581322.8A patent/CN108864076B/zh active Active
- 2013-09-10 AU AU2013315715A patent/AU2013315715A1/en not_active Abandoned
- 2013-09-10 PL PL13765893.6T patent/PL2895484T3/pl unknown
- 2013-09-10 HU HUE13765893A patent/HUE058085T2/hu unknown
- 2013-09-10 RS RS20220379A patent/RS63130B1/sr unknown
- 2013-09-10 KR KR1020157009037A patent/KR102216532B1/ko active IP Right Grant
- 2013-09-10 CN CN201380058586.0A patent/CN105073745B/zh active Active
- 2013-09-10 BR BR112015005227A patent/BR112015005227A2/pt not_active Application Discontinuation
- 2013-09-10 MY MYPI2015000454A patent/MY186824A/en unknown
- 2013-09-10 JP JP2015531307A patent/JP6430943B2/ja active Active
- 2013-09-10 SI SI201331971T patent/SI2895484T1/sl unknown
- 2013-09-10 MX MX2015003043A patent/MX2015003043A/es active IP Right Grant
- 2013-09-10 CN CN202210106457.5A patent/CN114533729A/zh active Pending
- 2013-09-10 HR HRP20220310TT patent/HRP20220310T1/hr unknown
- 2013-09-11 AR ARP130103240A patent/AR092522A1/es unknown
- 2013-09-11 TW TW102132762A patent/TWI627171B/zh active
- 2013-09-11 UY UY0001035024A patent/UY35024A/es unknown
- 2013-10-09 UA UAA201503339A patent/UA118747C2/uk unknown
-
2015
- 2015-02-22 IL IL237355A patent/IL237355B/en active IP Right Grant
- 2015-02-25 DO DO2015000039A patent/DOP2015000039A/es unknown
- 2015-02-27 PH PH12015500431A patent/PH12015500431A1/en unknown
- 2015-03-02 GT GT201500051A patent/GT201500051A/es unknown
- 2015-03-04 CL CL2015000529A patent/CL2015000529A1/es unknown
- 2015-03-10 TN TNP2015000091A patent/TN2015000091A1/fr unknown
- 2015-03-19 CR CR20150150A patent/CR20150150A/es unknown
-
2016
- 2016-01-18 HK HK16100495.2A patent/HK1212681A1/zh unknown
-
2017
- 2017-04-18 US US15/490,385 patent/US11008316B2/en active Active
-
2021
- 2021-04-14 US US17/230,385 patent/US20220073508A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220310T1 (hr) | Inhibitori glukozilceramid sintaze | |
| JP2015527406A5 (hr) | ||
| HRP20200226T1 (hr) | Inhibitor glukozilceramid sintaze | |
| HRP20210255T1 (hr) | Postupak priprave derivata karbamoilpiridona i međuprodukata | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| SA517390586B1 (ar) | مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
| CL2017002609A1 (es) | Compuestos derivados de pirazolopiridina hidrogenadas, inhibidores p2x7, composición farmacéutica que los comprende; proceso de preparación de estos; y su uso en el tratamiento de enfermedades oseas, sns, cardiovasculares, entre otras (divisional de cl 2655-2015) | |
| MD4490C1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| MX2019004019A (es) | Pirrolidinas sustituidas como moduladores cftr. | |
| MD4551B1 (ro) | Derivaţi pe bază de tetrahidroizochinoline şi N-(fenilfosfat)amide, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| WO2013170068A3 (en) | Nuclear transport modulators and uses thereof | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| WO2015031564A3 (en) | Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors | |
| PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
| NZ630099A (en) | Phenicol antibacterials | |
| IN2014MN00258A (hr) | ||
| SI2640734T1 (en) | Aminoglycosides and their uses in the treatment of genetic disorders | |
| MX344701B (es) | Derivados de pirrol como moduladores de nachr alfa 7. | |
| PE20220386A1 (es) | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b | |
| TN2015000271A1 (en) | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity | |
| WO2014101295A3 (zh) | 一种詹纳斯激酶（jaks）抑制活性的异恶唑衍生物 | |
| WO2009140341A3 (en) | Atorvastatin compositions | |
| IL273002B2 (en) | Transmuted imidazoquinolines | |
| TN2016000003A1 (en) | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MX2019000608A (es) | Derivados de panteteina para tratamiento de trastornos neurologicos. |